抗病毒藥物治療肝纖維化的市場規模、佔有率和成長分析：按病毒發病機制、藥物類別/作用機制、纖維化階段、最終用戶和地區分類－2026-2033年產業預測

2024 年全球用於治療肝纖維化的抗病毒藥物市場價值為 220 億美元，預計到 2033 年將從 2025 年的 244.2 億美元成長至 562.8 億美元，預測期（2026-2033 年）的複合年成長率為 11.0%。

全球抗病毒藥物肝纖維化市場的主要驅動力是慢性病毒性肝炎盛行率的不斷上升。慢性病毒性肝炎會增加肝纖維化進展的風險，從而持續催生對有效治療方法的需求。乙型和丙型肝炎病毒感染的持續存在凸顯了預防肝硬化和肝細胞癌等併發症的緊迫性，推動了抗病毒藥物研發領域的大量投資。市場正從療效有限的干擾素療法轉向強效的直接抗病毒藥物（DAA）和核苷類似物，這些藥物已被證實能夠透過抑制病毒來減輕肝纖維化。此外，篩檢和診斷技術的進步使得早期療育成為可能，從而最大限度地減少了晚期併發症。同時，人工智慧正在透過改進標靶識別、生物標記發現和臨床試驗設計，革新藥物研發，最終擴大商業性機會，並使全球患者能夠獲得多種多樣的抗病毒療法。

全球抗病毒藥物肝纖維化的市場促進因素

病毒性肝炎發生率的上升顯著增加了肝纖維化風險的患者數量，導致人們對有效抗病毒療法的關注度和需求日益成長。疾病盛行率的激增正在影響研究重點，並加速藥物研發資金的投入。相關人員積極將抗病毒療法納入治療通訊協定，從而提高了臨床認知度，並開展了更積極的公眾宣傳活動。隨著早期診斷和治療方法的普及，以及醫療服務提供者和保險公司尋求能夠阻止病情發展為嚴重肝病並減輕長期醫療需求的解決方案，這些努力正在推動市場持續成長。

全球抗病毒藥物肝纖維化市場面臨的限制因素

全球抗病毒藥物治療肝纖維化的市場面臨諸多限制因素，包括治療費用飆升和保險報銷範圍有限，導致患者難以獲得所需的治療。當患者面臨高額自付費用或保險覆蓋範圍不確定時，醫療服務提供者可能會延遲開立抗病毒藥物處方或考慮其他治療方案，從而阻礙市場滲透。此外，保險公司和醫療機構設定的嚴格合格標準進一步限制了符合治療條件的患者群體，降低了藥物的商業性吸引力，並阻礙了產品的大規模上市。這些准入障礙不僅減緩了收入成長，也阻礙了投資，並妨礙了創新治療方法被納入肝​​纖維化患者的標準治療方案。

全球抗病毒藥物肝纖維化的市場趨勢

全球肝纖維化抗病毒藥物市場正經歷著向精準醫療的顯著轉變，強調基於分子譜分析和生物標記選擇的個人化治療策略。研發人員日益專注於開發能夠特異性針對不同病毒基因型和特定纖維化路徑的抗病毒藥物。與診斷試劑生產商合作開發伴隨診斷試劑也日益普遍，這透過增強臨床療效和減少不必要的治療來提高患者照護品質。此外，保險公司和醫療服務提供者正優先考慮以療效為導向的療法，並加大對創新研發管線和先進商業模式的投資，以滿足患者的個人需求。這些措施最終將提升整體治療效果和患者滿意度。

目錄

介紹

• 調查目的
• 市場定義和範圍

調查方法

• 研究過程
• 二級資料和一級資料的方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態及展望

• 總體經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

關鍵市場分析

• 關鍵成功因素
• 影響市場的因素
• 主要投資機會
• 生態系測繪
• 2025年市場魅力指數
• PESTLE分析
• 監理情勢

全球抗病毒藥物治療肝纖維化的市場規模：依病毒病因分類

• 針對乙型肝炎病毒（HBV）
• 針對丙型C型肝炎病毒（HCV）

全球用於治療肝纖維化的抗病毒藥物市場規模：按藥物類別/作用機制分類

• 核苷/核苷酸類似物（NrtIs）
• 直接作用抗病毒藥物（DAAs）
• 干擾素療法

全球用於治療肝纖維化的抗病毒藥物市場規模：按纖維化進展階段分類

• 初期
• 進行性纖維化/肝硬化

用於治療肝纖維化的抗病毒藥物的全球市場規模：按最終用戶分類。

• 肝病中心
• 診斷和調查機構
• 專科藥房

用於治療肝纖維化的抗病毒藥物的全球市場規模：按地區分類

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太國家
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲國家

競爭資訊

• 前五大公司對比
• 主要企業2025年的市場定位
• 主要市場公司採取的策略
• 近期市場趨勢
• 企業市場占有率分析，2025 年
• 主要企業的完整公司簡介
  • 公司詳情
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 銷售收入年比比較（2023-2025 年）

主要企業簡介

• Gilead Sciences
• AbbVie
• Merck & Co.
• Bristol Myers Squibb
• Intercept Pharmaceuticals
• Hepion Pharmaceuticals
• Genfit
• Novartis
• Echosens
• Promethera Biosciences
• Syneos Health
• TFF Pharmaceuticals
• Enanta Pharmaceuticals
• Sernova Corp
• Immuron
• Aegerion Pharmaceuticals
• Zymeworks
• DURECT Corporation
• Addex Therapeutics
• Hologic

結論與建議

Global Liver Fibrosis Antiviral Agents Market size was valued at USD 22.0 Billion in 2024 and is poised to grow from USD 24.42 Billion in 2025 to USD 56.28 Billion by 2033, growing at a CAGR of 11.0% during the forecast period (2026-2033).

The global liver fibrosis antiviral agents market is primarily driven by the increasing prevalence of chronic viral hepatitis, which heightens the risk of fibrotic progression and creates ongoing demand for effective treatments. The persistence of hepatitis B and C infections has emphasized the urgency of preventing complications like cirrhosis and hepatocellular carcinoma, fostering significant investment in antiviral research. The market has transitioned from less effective interferon-based therapies to robust direct-acting antivirals and nucleos(t)ide analogs that have demonstrated the capability of reducing fibrosis through viral suppression. Additionally, enhanced screening and diagnostics have facilitated early intervention and minimized advanced-stage complications. Meanwhile, AI is revolutionizing drug discovery by improving target identification, biomarker discovery, and trial design, ultimately expanding commercial opportunities and patient access to diverse antiviral therapies worldwide.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Liver Fibrosis Antiviral Agents market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Liver Fibrosis Antiviral Agents Market Segments Analysis

Global liver fibrosis antiviral agents market is segmented by viral etiology, drug class/mechanism, fibrosis stage, end-user and region. Based on viral etiology, the market is segmented into Hepatitis B Virus (HBV) Directed and Hepatitis C Virus (HCV) Directed. Based on drug class/mechanism, the market is segmented into Nucleoside/Nucleotide Analogues (NrtIs), Direct-Acting Antivirals (DAAs) and Interferon Therapies. Based on fibrosis stage, the market is segmented into Early Stage and Advanced Fibrosis/Cirrhosis. Based on end-user, the market is segmented into Hepatology Centers, Diagnostic & Research Institutes and Specialized Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Liver Fibrosis Antiviral Agents Market

The increasing incidence of viral hepatitis has significantly broadened the number of patients susceptible to liver fibrosis, thereby intensifying the focus on and demand for effective antiviral treatments. This surge in disease prevalence drives research priorities and accelerates funding for drug development. Stakeholders are motivated to incorporate antiviral therapies into treatment protocols, leading to improved clinical awareness and outreach initiatives. Such efforts result in earlier diagnosis and increased adoption of therapies, facilitating continuous market growth as healthcare providers and payers look for solutions that can halt the progression to severe liver disease and lessen long-term healthcare requirements.

Restraints in the Global Liver Fibrosis Antiviral Agents Market

The Global Liver Fibrosis Antiviral Agents market faces significant constraints due to high treatment costs and limited reimbursement options, which hinder patient access to necessary therapies. When patients encounter considerable out-of-pocket expenses or inconsistent coverage, healthcare providers may opt to delay prescribing antiviral medications or consider alternative treatment strategies, ultimately reducing market uptake. Additionally, payers and healthcare systems that enforce strict eligibility criteria further limit the eligible population for treatment, diminishing commercial appeal and discouraging extensive product launches. Such access barriers not only slow revenue growth but also impede investments and the integration of innovative therapies into standard care for those affected by liver fibrosis.

Market Trends of the Global Liver Fibrosis Antiviral Agents Market

The Global Liver Fibrosis Antiviral Agents market is witnessing a significant trend towards precision therapeutics, emphasizing personalized treatment strategies driven by molecular profiling and biomarker selection. Developers are increasingly focusing on creating antiviral agents that specifically address various viral genotypes and target distinct fibrotic pathways. Collaborations with diagnostics companies to develop companion tests are becoming more common, enhancing patient care by improving clinical responses and minimizing unnecessary treatments. Additionally, payers and healthcare providers are prioritizing outcome-focused therapies, prompting investment in innovative pipeline assets and advanced commercial models that cater to the unique needs of patients, thus enhancing overall treatment efficacy and satisfaction.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Liver Fibrosis Antiviral Agents Market Size by Viral Etiology & CAGR (2026-2033)

• Market Overview
• Hepatitis B Virus (HBV) Directed
• Hepatitis C Virus (HCV) Directed

Global Liver Fibrosis Antiviral Agents Market Size by Drug Class/Mechanism & CAGR (2026-2033)

• Market Overview
• Nucleoside/Nucleotide Analogues (NrtIs)
• Direct-Acting Antivirals (DAAs)
• Interferon Therapies

Global Liver Fibrosis Antiviral Agents Market Size by Fibrosis Stage & CAGR (2026-2033)

• Market Overview
• Early Stage
• Advanced Fibrosis/Cirrhosis

Global Liver Fibrosis Antiviral Agents Market Size by End-User & CAGR (2026-2033)

• Market Overview
• Hepatology Centers
• Diagnostic & Research Institutes
• Specialized Pharmacies

Global Liver Fibrosis Antiviral Agents Market Size & CAGR (2026-2033)

• North America (Viral Etiology, Drug Class/Mechanism, Fibrosis Stage, End-User)
  • US
  • Canada
• Europe (Viral Etiology, Drug Class/Mechanism, Fibrosis Stage, End-User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Viral Etiology, Drug Class/Mechanism, Fibrosis Stage, End-User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Viral Etiology, Drug Class/Mechanism, Fibrosis Stage, End-User)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Viral Etiology, Drug Class/Mechanism, Fibrosis Stage, End-User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Gilead Sciences
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol Myers Squibb
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Intercept Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hepion Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Genfit
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Echosens
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Promethera Biosciences
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Syneos Health
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• TFF Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Enanta Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sernova Corp
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Immuron
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aegerion Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zymeworks
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• DURECT Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Addex Therapeutics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hologic
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations